Effectiveness and Cost-effectiveness of a VCoP to Empowerment of Patients With Ischaemic Heart Disease in PHC: Cluster-RCT (Empodera-dos)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03959631 |
|
Recruitment Status :
Recruiting
First Posted : May 22, 2019
Last Update Posted : March 30, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Objective: to evaluate the effectiveness and estimate the costs of a Virtual Community of Practice in the improvement of the activation of patients with Ischemic Heart Disease in Primary Care .
Methods:
Design: pragmatic randomized controlled multicentric trial. Setting: health centres belonging to the Autonomous Communities of Catalonia, Madrid and the Canary Islands. Population: 246 patients with Ischemic Heart Disease in Primary Care. Randomization: randomization will be central and automatically performed by the online "e-mpodera" platform and the assigned group will be communicated to the patient once he or she has entered the platform and completed baseline assessment. Intervention: the intervention group will be offered participation for 6 months in a Virtual Community of Practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals. The control group will receive usual care. Measurements: the main variable will be measured using the Patient Activation Measure questionnaire at baseline, 6, 12 and 18 months. Secondary variables: sociodemographic and clinical variables of the patients; knowledge test (questionnaire of risk cardiovascular factories , attitudes (Self-efficacy Managing Chronic Disease Scale ), adherence to Mediterranean diet (Mediterranean Diet), level of physical activity (International Physical Activity Questionnaire), medication adherence (Adherence Refill and Medication Scale (ARMS-e), depression (Patient Health Questionnaire), anxiety (Hospital Anxiety and Depression Scale), quality of life (EQ-5D-5L); variables related to the use of health resources; variables related to the use of the Virtual Community of Practice . Data will be collected from self-reported questionnaires and the electronic medical records. Analysis: a linear regression model of mixed effects will be estimated to estimate the effect of participating in the Virtual Community of Practice. In addition, subgroup analyses will be carried out and indicators of the functioning of the Virtual Community of Practice will be measured through techniques of Social Network Analysis and Control Charts. There will be an economic evaluation of the Virtual Community of Practice from the perspective of the National Health System and from the social perspective.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ischemic Heart Disease Chronic | Behavioral: Virtual Communities of practice | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 123 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Design: pragmatic randomized controlled trial, with two parallel arms, multicenter, 18 months of follow-up Setting Primary Care Centres belonging to the Autonomous Communities of Catalonia, (329), Madrid (262) and the Canary Islands (102). |
| Masking: | Double (Investigator, Outcomes Assessor) |
| Masking Description: | Investigator and outcomes Assessor don´t Know the intervention assigned to each patient |
| Primary Purpose: | Supportive Care |
| Official Title: | Effectiveness and Cost-effectiveness of a Virtual Intervention (VCoP) to Improve the Empowerment of Patients With Ischaemic Heart Disease in Primary Care: Cluster Randomized Controlled Trial |
| Actual Study Start Date : | January 11, 2021 |
| Estimated Primary Completion Date : | November 30, 2022 |
| Estimated Study Completion Date : | November 30, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Intervention group
The intervention group will be offered participation for 6 months in a Virtual Communities of practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
|
Behavioral: Virtual Communities of practice
based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals. |
|
No Intervention: Control group
The control group will not receive any specific intervention. They receive usual care according to actually clinical practice guidelines.
|
- Patient Activation Measure questionnaire [ Time Frame: Patient Activation Measure measured at 18 months ]It has 13 items, measured with a Likert scale (from 1 to 4). This questionnaire values activation in patients with chronic diseases. It evaluates people's knowledge and skills in self-care. Puntuation is 0 to 100 (best puntuation)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Active diagnosis of ischemic heart disease in the year prior to inclusion in the study; have Internet at home or phone
- be able to follow the requirements of the study
- having signed informed consent for participation in the study.
Exclusion Criteria:
- low probability of cooperation in the study
- bystanders or displaced status
- institutionalized, with a terminal illness, physical or mental disability that prevents respond to questionnaires properly.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03959631
| Contact: Garrido Elustondo, Dr. | 913019405 | sgarrido@salud.madrid.org |
| Spain | |
| Sofía Garrido elustondo | Recruiting |
| Madrid, Spain, 28028 | |
| Contact: Garrido Elustondo, Dr. 913016400 ext 204 sgarrido@salud.madrid.org | |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Sofia Garrido Elustondo, Epidemiologist, Gerencia de Atención Primaria, Madrid |
| ClinicalTrials.gov Identifier: | NCT03959631 |
| Other Study ID Numbers: |
PI18/01397 PI18/01333 ( Other Grant/Funding Number: Servicio de Evaluación del Servicio canario de la Salud ) PI 18/01404 ( Other Grant/Funding Number: Avedis Donabedian Research Institute ) |
| First Posted: | May 22, 2019 Key Record Dates |
| Last Update Posted: | March 30, 2021 |
| Last Verified: | March 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Data will be collected from self-reported questionnaires and the electronic medical records. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
| Time Frame: | 18 months |
| Access Criteria: | Only researchers can Access to the study data. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Ischemic Heart Disease Virtual Community of Practice empowerment |
|
Heart Diseases Myocardial Ischemia Coronary Artery Disease Ischemia Pathologic Processes |
Cardiovascular Diseases Vascular Diseases Coronary Disease Arteriosclerosis Arterial Occlusive Diseases |

